ArticleBMC cancer2015
Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: a population-based study in North Portugal.Cancer causes & control : CCC · 2026Article
- When Local Beats Systemic: Durable Control of Metastatic Undifferentiated Uterine Sarcoma and Surveillance Uncovering a Second Primary.Acta medica Lituanica · 2026Article
- Endometrial Carcinoma and Associated Secondary Neoplasia: The Role of Clinical Features, Pathology, and Comorbidities in a University-Affiliated Clinical Center from Western Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.International journal of cancer · 2025Article
- Trends in endometrial cancer incidence in the United States by race/ethnicity and age of onset from 2000 to 2019.American journal of epidemiology · 2025Article
- Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018.Journal of neuro-oncology · 2023Article
- Clinical characteristics and survival of second primary breast carcinoma with extramammary malignancies.Frontiers in oncology · 2023Article
- Analysis and prediction of second primary malignancy in patients with breast cancer.Molecular and clinical oncology · 2022Article
- Influence of Photodynamic Therapy on Lichen Sclerosus with Neoplastic Background.Journal of clinical medicine · 2022Article
- Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A population-based analysis.Cancer medicine · 2021Article
- Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice.PloS one · 2020Article
- The association between histological subtype of a first primary endometrial cancer and second cancer risk.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2019Article
- The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus.Cancer medicine · 2018Article
- Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.Journal of gynecologic oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies assessing second primary malignancies (SPMs) after uterine cancer have been conducted in Western populations with conflicting results. This study aimed to define the incidence and risk of SPMs in Taiwanese patients with an initial diagnosis of uterine cancer.
methodsUsing population-based data from the Taiwan Cancer Registry for the period 1979-2008, we quantified standardized incidence ratios (SIRs) among 11,571 women with an initial diagnosis of uterine cancer.
resultsAmong the 11,571 women, 555 (4.80%) developed at least one SPM during 69,987 person-years of follow-up. There was a 71% increased risk of SPM following uterine cancer (SIR=1.71, 95% CI, 1.57-1.86), with higher risks in the vagina/vulva (SIR=9.06), small intestine (SIR=8.45), ovary (SIR=4.15), urinary bladder (SIR=2.31), kidney (SIR=2.24), colorectum (SIR=2.24), lung (SIR=1.96), and breast (SIR=1.43). The risk of SPM was found to be the highest within the first 5 years after diagnosis of uterine cancer, with surveillance bias possibly contributing to the extremely high risk observed in the first follow-up year. The overall risk and pattern of SPM development observed in this study differed from those previously reported in Western populations, possibly because of the methodology and shorter follow-up period employed in this study. The cumulative incidence of SPMs was significantly higher in older patients (≥50 years) than in younger patients (P<0.001).
conclusionsTo our knowledge, this is the first study in an Asian population to report 71% increased risk in SPMs in women previously diagnosed with uterine cancer. A younger age at diagnosis of uterine cancer conferred an increased risk of second malignancies, and SPMs worsened survivorship in patients who survived uterine cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.